Under Medicare, CAR T-Cell Therapy Now Available Nationwide

The Centers for Medicare & Medicaid Services (CMS) have finalized nationwide coverage of chimeric antigen receptor (CAR) T-cell therapy, replacing the previous policy under which the decision of treatment coverage was left to Medicare's regional administrators. "As the first type of FDA-approved gene therapy, CAR T-cell therapies are an important scientific advancement in this promising new area of medicine and provide treatment options for some patients who had nowhere else to turn," c...
Continue reading

HSCT: Improving Communication Between the Transplant Center and the Oncologist With Miguel-Angel Perales, MD

While hematopoietic stem cell transplant (HSCT) offers a curative treatment option for many patients, oncologists face unique challenges, including the underutilization of transplant, the need for improved communication between the transplant center and the community oncologist, and the implementation of CAR T-cell therapy. In this interview with i3 Health, Miguel-Angel Perales, MD, addresses these challenges and discusses the importance of clinical trial enrollment and innovative programs that ...
Continue reading

CAR T-Cell Therapies: Survey of Oncology Nurses Reveals Much to Be Learned

​ Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy in which a patient's own T cells are collected and genetically altered to target cancer cells. Although CAR T-cell therapies have shown encouraging results in patients with acute lymphoblastic leukemia and B-cell lymphomas, they are associated with several serious adverse events, including cytokine release syndrome, neurotoxicity, tumor lysis syndrome, and graft-versus-host disease.  In light of the growing use of C...
Continue reading

Multiple Myeloma: bb2121 CAR T-Cell Therapy With James Kochenderfer, MD

Chimeric antigen receptor (CAR) T-cell therapy has shown great promise in hematologic malignancies, with treatments currently FDA approved for aggressive, refractory non-Hodgkin lymphoma and for relapsed/refractory acute lymphoblastic leukemia in patients up to the age of 25. Now, a phase 1 clinical trial of bb2121, a CAR T-cell therapy targeting B-cell maturation antigen (BCMA), has demonstrated antitumor activity in patients with heavily pretreated multiple myeloma. In this interview with i3 H...
Continue reading

Bb2121: New CAR T-Cell Therapy for Multiple Myeloma

A phase 1 clinical trial reports that bb2121, a chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), has shown antitumor activity in relapsed/refractory multiple myeloma. A form of immunotherapy, CAR T-cell therapy involves adding a CAR to the patient's cytotoxic T cells, transforming the T cells into CAR T cells. After this modification, which is done in the laboratory, the CAR T cells are reinjected into the patient's bloodstream, where they multiply and a...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.